Loading
Life sciences · Journal article
Safety and Risk of Pharmacotherapy · October 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The rapid increase in the prevalence of obesity and the rise in eating disorders require a revision of treatment approaches. Modern clinical practice supplements the therapeutic arsenal of lifestyle modification and diet therapy with next-generation medicinal products, inevitably raising issues of pharmacotherapy safety, long-term risks, and nutritional support for physicians. The interview discusses fundamental changes in diet and the role of ultraprocessed foods as a risk factor for metabolic catastrophes. The possibilities and limitations of nutrigenomics are examined, in particular in the context of polymorphisms in folate metabolism genes. Special attention is given to the safety of glucagon-like peptide-1 (GLP-1) receptor agonists: the risks of gastroparesis, sarcopenia, and micronutrient deficiency are analyzed. The paradox of sibutramine use in Russian and international clinical practice is discussed. The conversation concludes with the problem of the absence of targeted drugs for anorexia nervosa and the prospects for modulation of cannabinoid and ghrelin receptors. The treatment of nutrition-related diseases requires an interdisciplinary approach, in which pharmacological intervention is necessarily accompanied by strict nutritional control and assessment of individual genetic risks.